Premarket Decliner
SNTI Senti Biosciences5.57-0.02-0.4%
Premarket:5.20-0.37 (-6.6%)
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
Globe NewswireMon, 16-Dec 8:00 AM
SNTI Senti Biosciences5.14+2.64+105.6%
Premarket:4.18-0.96 (-18.7%)
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting
Globe NewswireWed, 5-Oct 8:01 AM
